SW · NWRN.SW
Newron Pharmaceuticals S.p.A.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Bresso, MI 20091
- Website
- newron.com
Price · as of 2024-12-31
$14.30
Market cap 371.27M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $73.60 | +414.69% |
| Intrinsic Value(DCF) | $3,128.61 | +21,778.39% |
| Graham-Dodd Method(GD) | $4.10 | -71.33% |
| Graham Formula(GF) | $363.30 | +2,440.56% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $6.79 | $35.08 | $0.00 | $0.00 | $165.90 |
| 2011 | $2.32 | $164.57 | $0.00 | $0.00 | $45.00 |
| 2012 | $8.20 | $651.94 | $179.49 | $1.80 | $0.00 |
| 2013 | $17.60 | $361.30 | $0.97 | $0.00 | $28.60 |
| 2014 | $33.00 | $40.02 | $1.31 | $0.00 | $33.80 |
| 2015 | $18.90 | $28.77 | $1.17 | $0.00 | $0.00 |
| 2016 | $27.80 | $53.37 | $26.48 | $0.00 | $0.00 |
| 2017 | $9.80 | $66.97 | $2.24 | $2.40 | $0.00 |
| 2018 | $8.59 | $24.20 | $1.47 | $0.00 | $46.30 |
| 2019 | $5.45 | $29.07 | $0.56 | $0.00 | $0.00 |
| 2020 | $2.88 | $31.82 | $0.00 | $0.00 | $17.60 |
| 2021 | $1.29 | $30.72 | $0.00 | $0.00 | $0.00 |
| 2022 | $5.92 | $25.77 | $0.00 | $0.00 | $0.00 |
| 2023 | $7.62 | $30.08 | $0.00 | $0.00 | $0.00 |
| 2024 | $8.85 | $78.73 | $461.82 | $4.10 | $363.30 |
AI valuation
Our deep-learning model estimates Newron Pharmaceuticals S.p.A.'s (NWRN.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $73.60
- Current price
- $14.30
- AI upside
- +414.69%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3,128.61
+21,778.39% upside
Graham-Dodd
$4.10
-71.33% upside
Graham Formula
$363.30
+2,440.56% upside
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
- CEO
- Stefan Weber
- Employees
- 22
- Beta
- 0.70
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3,128.61 ÷ $14.30) − 1 = +21,778.39% (DCF, example).